Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lin, Shu Fu ^a   Lin, Jen Der ^a   Chou, Ting Chao ^b   Huang, Yu Yao ^a   Wong, Richard J ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELINOSTAT; DNA; DOCETAXEL; DOUBLE STRANDED DNA; DOXORUBICIN; HISTONE H3; HISTONE H4; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG UTILIZATION; FEMALE; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACETYLATION; ANIMALS; CELL DEATH; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROID NEOPLASMS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885400899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077684     Document Type: Article

References (53)

1. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R, (2013) Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 9: 178-184. doi:10.1038/nrendo.2012.257. PubMed: 23358352.
2. Davies L, Welch HG, (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167. doi:10.1001/jama.295.18.2164. PubMed: 16684987.
3. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM, (2010) Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 148: 1147-1153; discussion: 21134545.
4. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893. doi:10.1158/0008-5472.CAN-09-0727. PubMed: 19487299.
5. Wirth LJ, Ross DS, Randolph GW, Cunnane ME, Sadow PM, (2013) Case records of the Massachusetts General Hospital. Case 5-2013. p. A 52-year-old woman with a mass in the thyroid. N Engl J Med 368: 664-673.
6. Marks PA, (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799: 717-725. doi:10.1016/j.bbagrm.2010.05.008. PubMed: 20594930.
7. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. doi:10.1038/nrd2133. PubMed: 16955068.
8. Minucci S, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51. doi:10.1038/nrc1779. PubMed: 16397526.
9. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, et al. (2010) Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29: 105-116. doi:10.1038/onc.2009.306. PubMed: 19802013.
10. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, et al. (2002) Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984-990. doi:10.1067/msy.2002.128690. PubMed: 12490845.
11. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, et al. (2004) Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145: 2865-2875. doi:10.1210/en.2003-1258. PubMed: 14976143.
12. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG, (2001) Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11: 315-325. doi:10.1089/10507250152039046. PubMed: 11349829.
13. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, et al. (2005) Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11: 3958-3965. doi:10.1158/1078-0432.CCR-03-0776. PubMed: 15897598.
14. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP, (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12: 5570-5577. doi:10.1158/1078-0432.CCR-06-0367. PubMed: 17000694.
15. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, et al. (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472. doi:10.1677/joe.1.06970. PubMed: 17088416.
16. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G, (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14: 839-845. doi:10.1677/ERC-07-0096. PubMed: 17914112.
17. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728. PubMed: 12939461.
18. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589. doi:10.1042/BJ20070779. PubMed: 17868033.
19. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, et al. (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5: 2086-2095. doi:10.1158/1535-7163.MCT-06-0111. PubMed: 16928830.
20. Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, et al. (2010) Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol 184: 2557-2564. doi:10.1016/j.juro.2010.07.035. PubMed: 21030039.
21. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, et al. (2010) A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103: 12-17. doi:10.1038/sj.bjc.6605726. PubMed: 20588278.
22. Topotarget, A/S (Copenhagen). Available: http://www.topotarget.com/belinostat/belinostat-clinical-studies.aspx. [Accessed 2013 April 5].
23. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, et al. (2004) The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600. doi:10.1158/0008-5472.CAN-03-2631. PubMed: 15059916.
24. Marks PA, (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066. doi:10.1517/13543784.2010.510514. PubMed: 20687783.
25. New M, Olzscha H, La Thangue NB, (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6: 637-656. doi:10.1016/j.molonc.2012.09.003. PubMed: 23141799.
26. Misteli T, Soutoglou E, (2009) The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol 10: 243-254. doi:10.1038/nrm2651. PubMed: 19277046.
27. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M, (2004) Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 24: 9305-9316. doi:10.1128/MCB.24.21.9305-9316.2004. PubMed: 15485900.
28. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, et al. (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22: 1104-1139. doi:10.1089/thy.2012.0302. PubMed: 23130564.
29. Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, et al. (2012) Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLOS ONE 7: e46726. doi:10.1371/journal.pone.0046726. PubMed: 23077520.
30. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681. doi:10.1124/pr.58.3.10. PubMed: 16968952.
31. Chou TC, Martin N, (2005) CompuSyn for Drug Combinations: PC Software and Users Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations and the Determination of IC50, ED50, and LD50 Values. Paramus, NJ: ComboSyn. Available: www.combosyn.com.
32. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, et al. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 673-678. doi:10.1073/pnas.0408732102. PubMed: 15637150.
33. Xing M, (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13: 184-199. doi:10.1038/nrc3431. PubMed: 23429735.
34. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW, (2011) Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17: 6482-6489. doi:10.1158/1078-0432.CCR-11-0933. PubMed: 21831957.
35. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) γH2AX and cancer. Nat Rev Cancer 8: 957-967. doi:10.1038/nrc2523. PubMed: 19005492.
36. Neal JA, Meek K, (2011) Choosing the right path: does DNA-PK help make the decision? Mutat Res 711: 73-86. doi:10.1016/j.mrfmmm.2011.02.010. PubMed: 21376743.
37. Moynahan ME, Jasin M, (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11: 196-207. doi:10.1038/nrm2851. PubMed: 20177395.
38. Sy SM, Huen MS, Chen J, (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106: 7155-7160. doi:10.1073/pnas.0811159106. PubMed: 19369211.
39. Ciccia A, Elledge SJ, (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40: 179-204. doi:10.1016/j.molcel.2010.09.019. PubMed: 20965415.
40. San Filippo J, Sung P, Klein H, (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77: 229-257. doi:10.1146/annurev.biochem.77.061306.125255. PubMed: 18275380.
41. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, et al. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922. doi:10.1158/1078-0432.CCR-04-2088. PubMed: 16000590.
42. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, et al. (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 104: 19482-19487. doi:10.1073/pnas.0707828104. PubMed: 18042714.
43. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, et al. (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLOS ONE 5: e11208. doi:10.1371/journal.pone.0011208. PubMed: 20585447.
44. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, et al. (2010) Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17: 1144-1151. doi:10.1038/nsmb.1899. PubMed: 20802485.
45. Kotian S, Liyanarachchi S, Zelent A, Parvin JD, (2011) Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 286: 7722-7726. doi:10.1074/jbc.C110.194233. PubMed: 21247901.
46. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, et al. (2012) The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97: 517-524. doi:10.1210/jc.2011-0618. PubMed: 22170714.
47. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF, (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468. doi:10.1126/science.6093249. PubMed: 6093249.
48. Ain KB, Egorin MJ, DeSimone PA, (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10: 587-594. doi:10.1089/thy.2000.10.587. PubMed: 10958311.
49. Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, et al. (2013) Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol [Epub ahead of print]. PubMed: 23824064.
50. Ohta K, Pang XP, Berg L, Hershman JM, (1997) Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82: 2633-2638. doi:10.1210/jc.82.8.2633. PubMed: 9253346.
51. Huang YY, Yu Z, Lin SF, Li S, Fong Y, et al. (2007) Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 92: 1965-1970. doi:10.1210/jc.2007-0040. PubMed: 17327376.
52. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, et al. (2007) Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142: 976-983; discussion: 18063085.
53. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341. doi:10.1210/jc.2008-1102. PubMed: 18713817.